Citations

Institution: Mayo Clinic Clear

Showing 10 of 108119 citations.

Preclinical ImmunoPET Imaging of Thyroid-Stimulating Hormone Receptor Expression in Thyroid Cancer using [ 64 Cu]Cu-NOTA-TSHR-Ab
Gleba, Justyna J., Muzik, Otto , Copland, John A. , Cai, Hancheng , Cai, Hancheng , Fu, Wenhui , Parent, Ephraim E. , Gleba, Justyna J., Knight, Joshua A.

Molecular Pharmaceutics | May 22, 2025 | Volume: 22 | Issue: 7 | Pages: 4056-4067

10.1021/acs.molpharmaceut.5c00325 | PMID 40403201 Get It

Classic hairy cell leukemia and concomitant smoldering myeloma
Jum’ah, Husam , Viswanatha, David S., Viswanatha, David

Blood | May 22, 2025 | Volume: 145 | Issue: 21 | Pages: 2533-2533

10.1182/blood.2025028465 | PMID 40402524 Get It

Blitzing ALL with blinatumomab
Litzow, Mark R.

Blood | May 22, 2025 | Volume: 145 | Issue: 21 | Pages: 2400-2402

10.1182/blood.2025028576 | PMID 40402527 Get It

AI Streamlines Prostate Pathology Data Extraction
Basourakos, Spyridon P. , Shoag, Jonathan E. , Basourakos, Spyridon

NEJM AI | May 22, 2025 | Volume: 2 | Issue: 6 | Pages: No page available

10.1056/aie2500388 | PMID 42932547 Get It

Prescribing controlled substances in sleep medicine clinics: an overview of legal issues and best safety practices
Silber, Michael H. , Rushlow, David , Ramar, Kannan , Kolla, Bhanu Prakash , Mansukhani, Meghna P.

Journal of Clinical Sleep Medicine | May 22, 2025 | Volume: 21 | Issue: 10 | Pages: 1799-1807

10.5664/jcsm.11770 | PMID 40400277 Get It

A Multimodality Review of Thumb Metacarpophalangeal Joint Injuries
Haug, Logan P. , Long, Jeremiah R. , Noland, Shelley S. , Melville, David M. , Flug, Jonathan A.

Roentgen Ray Review | May 22, 2025 | Volume: 1 | Issue: 2 | Pages: No page available

10.2214/r3j.24.01031 Get It

Low Antigen Titre Disseminated Cryptococcosis in Immunocompromised Hosts: Two Challenging Case Reports
Agarwal, Srishty , Jones, Angela , Chitale, Rohit , Durvasula, Ravindra, Oring, Justin , Rathod, Vaishnavi M , Hussain, Muhammad , Chitale, Rohit A , Oring, Justin M, Agarwal, Srishty, Hussain, Muhammad

American Journal of Case Reports | May 22, 2025 | Volume: 26 | Issue: No issue available | Pages: No page available

10.12659/ajcr.946589 | PMID 40515382 Get It

Thoracic Deformity in Fibrodysplasia Ossificans Progressiva
Kaplan, Frederick S. , Sponseller, Paul D. , Pignolo, Robert J. , Sponseller, Paul D , Kaplan, Frederick S

JBJS Reviews | May 22, 2025 | Volume: 13 | Issue: 5 | Pages: No page available

10.2106/jbjs.rvw.25.00042 | PMID 40403126 Get It

» Fibrodysplasia ossificans progressiva (FOP), the most severe form of heterotopic ossification (HO) in humans, may lead to severe thoracic deformity (TD) and thoracic insufficiency syndrome (TIS), the most common cause of mortality in individuals with FOP. » In this study, we examine the multiple causes of TD in FOP and propose a dynamic model for the development and evolution of TD that can be used to guide clinical care. This model posits that multiple factors, all originating from the causative gain-of-function mutation in activin receptor A, type 1, lead to TD in FOP. » Factors that lead to TD in FOP include early developmental costovertebral and facet joint arthropathy and joint ankylosis, progressive episodic flare-ups (both trauma induced or spontaneous) and subsequent HO, dysregulated soft tissue sensitivity to mechanical stimuli, growth plate dysregulation, and congenital rib fusions. These factors contribute to TD in FOP through a combination of intra-articular and extra-articular mechanisms, all amplified by growth. » Although FOP is a rare condition, it is illustrative of how a mutation in a critical receptor in the bone morphogenetic protein signaling pathway can cause a litany of musculoskeletal dysfunction that can lead to life-threatening consequences. Clinicians caring for individuals who have FOP must be aware of the occurrence, evolution, and implications of progressive TD and resultant TIS so that appropriate preventive measures such as avoidance of pulmonary infections, incentive spirometry, and diaphragmatic strengthening can be instituted.
Efficacy and Safety of Cryoballoon Versus Radiofrequency Ablation for Persistent Atrial Fibrillation: A Meta-Analysis of Randomized Controlled Trials
Burhan, Muhammad , Balbaa, Elsayed, Imtiaz, Zeeshan , Ibrahim, Ahmed M. , Virk, Hafeez Ul Hassan , Munir, Muhammad Bilal, Munir, Muhammad Bilal , Burhan, Muhammad , Munir, Muhammad Bilal , Burhan, Muhammad , Ibrahim, Ahmed , Balbaa, Elsayed , Naeem, Farhan , Qamar, Usama , Tabassum, Shehroze , Ahmed, Raheel , Asad, Zain Ul Abideen

Cardiology in Review | May 22, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1097/crd.0000000000000947 | PMID 40401921 Get It

Managing persistent atrial fibrillation (AF) remains challenging due to its complex arrhythmic substrate, and pulmonary vein isolation through catheter ablation remains the primary treatment. This meta-analysis aims to compare the efficacy and safety outcomes of cryoballoon ablation (CBA) and radiofrequency ablation (RFA) in patients with persistent AF to provide evidence-based insights for clinical decision-making. A systematic search of PubMed, Embase, and Cochrane Central was conducted following PRISMA guidelines. Randomized controlled trials (RCTs) comparing CBA and RFA in persistent AF were included. Data on efficacy, safety, and procedural outcomes were pooled in the form of odds ratios (ORs) or mean differences (MDs) with corresponding 95% confidence intervals (CIs) using the random effects model in the Review Manager (RevMan) software. Four RCTs comprising 899 patients were included in our analysis. There were no significant differences between CBA and RFA in terms of AF recurrence, atrial tachycardia/flutter recurrence, or any arrhythmia recurrence during a mean follow-up period of 18 months after ablation. Procedure time was significantly shorter with CBA (MD: −44.85 minutes, 95% CI: −56.46 to −32.24, P < 0.01), while fluoroscopy time was comparable between the 2 groups (MD: 4.31 minutes, 95% CI: −1.79 to 10.40, P = 0.17). Safety outcomes, including overall complications, phrenic nerve palsy, access-site complications, and pericardial effusion, showed no significant differences between the 2 groups. CBA and RFA show similar rates of atrial arrhythmia recurrence and periprocedural complications in the treatment of persistent AF, while CBA offers the advantage of a shorter procedure time.
Functional analysis across model systems implicates ribosomal proteins in growth and proliferation defects associated with hypoplastic left heart syndrome
Nielsen, Tanja , Kervadec, Anaïs , Theis, Jeanne L. , Marchant, James , Romero, Michaela, Marchetti, Katya , Lamba, Aashna, Berenguer, Marie , Walls, Stanley M. , Schroeder, Analyne , Birker, Katja , Duester, Greg, Grossfeld, Paul, Bodmer, Rolf , Colas, Alexandre R. , Marchetti, Katya , Berenguer, Marie , Nelson, Timothy J , Olson, Timothy M , Ocorr, Karen , Bodmer, Rolf , Vogler, Georg , Colas, Alexandre R , Theis, Jeanne L , Missinato, Maria A , Romero, Michaela, Zeng, Xin-Xin I. , Grossfeld, Paul, Nelson, Timothy J. , Olson, Timothy M. , Ocorr, Karen , Vogler, Georg

eLife | May 22, 2025 | Volume: 14 | Issue: No issue available | Pages: No page available

10.7554/elife.106231 | PMID 41379537 Get It

Hypoplastic left heart syndrome (HLHS) is the most lethal congenital heart disease (CHD) whose genetic basis remains elusive, likely due to oligogenic complexity. To identify regulators of cardiomyocyte (CM) proliferation relevant to HLHS, we performed a genome-wide siRNA screen in human iPSC-derived CMs, revealing ribosomal protein (RP) genes as the most prominent effectors of CM proliferation. Whole-genome sequencing of 25 HLHS proband–parent trios similarly showed enrichment of rare RP gene variants, including a damaging RPS15A promoter variant shared in a familial CHD case. Cross-species functional analyses demonstrated that perturbation of RP genes impairs cardiac growth: knockdown of RPS15A, RPS17, RPL26L1, RPL39, or RPS15 reduced CM proliferation, caused cardiac malformations in Drosophila , and produced hypoplastic or dysfunctional hearts in zebrafish. Genetic interactions between RP genes and key cardiac transcription factors (TBX5 and NKX2–7) further support their developmental role. Importantly, p53 suppression or Hippo activation partially rescued RP deficiency phenotypes. Together, these findings implicate RP genes as critical regulators of cardiogenesis and candidate contributors to HLHS.